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Background: In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we
measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor – TIMP-2 (tissue inhibitor of
MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor – TIMP-1, adiponectin, as well as pro-inflammatory
and procancerogenic thrombospondin-1 (TSP-1).
Design and patients: The study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum
concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured
by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months
(visit 3), 6 to 8 months (visit 4) and 15–18 months after radioiodine administration (visit 5).
Results: There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and
TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1
(from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to
5, respectively (p < 0.01). Further analysis revealed no significant change in MMP-2/TIMP-2 ratio, but there was a
significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in free MMP-9 concentrations.
Conclusions: Our data reveal a significant and sustained increase in serum adiponectin, as well as possible
decrease of free MMP-9 concentration after radioiodine administration. In contrast, there was no significant change
of TSP-1. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of
subsequent cardiovascular and neoplastic disease.
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The term matrix metalloproteinases (MMPs) refers to a
group of enzymes that physiologically remodel extracel-
lular matrix, but also contribute to development of vari-
ous pathological states, such as neoplasms, inflammatory
and cardiovascular diseases [1]. Furthermore, increased
activity of MMPs in blood vessels has been implicated in
formation of aneurysms [2], while formation of unstable
atherosclerotic plaques, as a result of locally increased* Correspondence: alewin@csk.umed.lodz.pl
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reproduction in any medium, provided the oractivity of MMPs, might in turn lead to an increased risk
thrombotic and embolic events, including myocardial
infarctions and strokes [3-5].
Adiponectin is a plasma protein secreted from adi-
pocytes in relatively large amounts, where decreased
adiponectin secretion has been directly linked with the
development of type 2 diabetes mellitus and metabolic
syndrome, known to be associated with an increased
risk of cardiovascular disease. There is ample evidence
demonstrating that adiponectin has anti-inflammatory,
anti-atherosclerotic and vasoprotective actions, affects
signaling in myocardial cells and exerts beneficial ac-
tions on the heart after pressure overload and ischemia-
reperfusion injury [6,7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Concentrations of TSH, free T4, free T3, glucose
and lipids at the beginning and at the end of the study









Mean SD Mean SD
TSH* [μIU/ml] 0.10 0.20 3.74 3.15 0.0003
Free T4* [pmol/l] 26.8 15.6 14.42 2.23 0.0008
Free T3* [pmol/l] 10.1 5.3 4.87 1.01 0.0003
Glucose [mg/dl] 93 13 90 12 0.62
Total cholesterol [mg/dl] 197 37 237 56 0.012
LDL-cholesterol [mg/dl] 108 38 153 54 0.001
HDL-cholesterol [mg/dl] 61 17 61 14 0.16
Triglycerides [mg/dl] 121 118 116 58 0.21
*Reference ranges: free T4 11.5-22.7 pmol/l, free T3 2.76-6.45 pmol/l, TSH 0.4-4
μIU/ml 1 pmol/l x 0.0777= ng/dl.
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of five (5) structurally related extracellular glycopro-
teins that plays a major role in cell-matrix and cell-
cell interactions. TSP-1 is highly expressed in obese,
insulin-resistant subjects. When released to the matrix,
matricellular proteins associate with growth factors, cy-
tokines, and other bioactive effectors and bind to cell
surface receptors transducing signaling cascades. TSP-1
is highly correlated with adipose inflammation [8]; and
is decreased by pioglitazone [9], though there is also
evidence of possible protective properties in circum-
stances, such as cardiac remodeling after injury [10].
Thrombospondin has been also found to be secreted by
thyrocytes in a pattern that is opposite to thyroglobulin
[11], and subsequently TSP-1 has also been identified
as a potential regulator of angiogenesis and tumour
progression [12].
Recent studies [13,14], demonstrated that even sub-
clinical thyrotoxicosis may be independently associated,
with an increased cardiovascular morbidity and mortal-
ity, though there are still several issues pertaining this
subject [15]. Pharmacological treatment of thyrotoxicosis
occasionally causes agranulocytosis, and this complica-
tion, unfortunately, cannot be prevented by routine full
blood count monitoring of asymptomatic patients [16].
Pharmacological treatment of thyrotoxicosis has other
drawbacks, as it generally does not lead to permanent
cure in subjects with toxic multinodular goitre, while
relapse in subjects with Graves’ disease may exceed 50
per cent. For these reasons radioactive iodine treatment
(RIT) has been used to treat thyrotoxicosis since 1940's.
In the USA, and less commonly in Europe, RIT is pre-
scribed even for children with Graves’s disease [17].
There are, however, some recent data [18], suggestive
of an increase in cardiovascular and cancer mortality
after RIT, at least in some subjects, though a definite
causality remains to be proven [19]. Given potential
option of surgery, the safety of RIT is of paramount
importance from the clinical view-point. For reasons
outlined above, we have endeavoured to prospectively
investigate whether serum concentrations of selected
risk markers of cardiovascular and neoplastic diseases,
such as matrix metalloproteinases (MMP-2, MMP-9),
their inhibitors (TIMP-1, TIMP-2), adiponectin and TSP-
1 might change following radioiodine treatment of thy-
rotoxicosis.
Design and patients
The study involved 23 patients (three males) age 53±12
(mean±SD), BMI 26.5±4.6 kg/m2 years treated with
radioiodine for thyrotoxicosis. Serum concentrations
TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1,
TIMP-2, total adiponectin and TSP-1 were measured
just before radioiodine administration (visit 1), andsubsequently, after 7 days (visit 2), 3 months (visit 3), 6 to
8 months (visit 4) and 15–18 months after radioiodine
administration (visit 5).
Radioactive iodine was administered according to the
protocol that involved thyroid goitre or nodule volume
and radioiodine uptake (T24) and radioiodine activity
for 1.0 gram of thyroid tissue in thyroid with dose de-
pending on the type of thyroid disease. In this method
the formula applied for calculation of the dose of radio-
iodine was as follows [20]:
Dose of radioiodine mCið Þ
¼ Thyroid mass gð Þ  radioiodine activity for 1:0 g of thyroid tissue μCi=gð Þ
T24 %ð Þ  10
where:
-1.0 g of thyroid tissue mass means 1.0 ml of thyroid
volume,
– radioiodine activity to be administered in adults: in
Graves’ disease 80–150 μCi/1.0 g of thyroid tissue,
in toxic thyroid nodule 150 μCi/1.0 g of thyroid
tissue, in toxic goitre 100-150 μCi/1.0 g of thyroid
tissue [21],
– T24 (%) - radioiodine uptake [20].
Measurements of MMP-2, MMP-9, TIMP-1, TIMP-2,
adiponectin and TSP-1 were performed by R & D sys-
tems immunoassays (Human Quantikine ELISA kit, for
MMPs and TIMPs, Human Total Adiponectin /Acrp30
Quantikine ELISA Kit, human TSP-1 Quantikine ELISA
Kit - catalogue numbers: DMP2F0 for MMP-2, DMP900
for MMP-9, DTM100 for TIMP-1, DTM200 for TIMP-
2, DRP300 for adiponectin and DTSP10 for TSP-1).
Table 3 Descriptive statistics for MMP-2/TIMP-2 ratio and
MMP-9/TIMP-1 ratio at five (5) consecutive visits – before
and after radioiodine therapy, presented with probability
values (p-values) of Kruskal-Wallis’ ANOVA for repeated
measures design
VISIT: n Mean ± SD p-value
MMP-2/TIMP-2 before radioiodine 23 2.96 ± 0.54 0.34
7 days post 21 2.65 ± 0.43
3 months post 23 2.68 ± 0.57
6 - 8 months post 23 3.00 ± 0.65
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Given the dependent character of the data (repeated
measurements in the same subjects), the data were ana-
lysed by means of simple descriptive statistics of loca-
tion and dispersion as well as Friedman ANOVA for
dependent samples. If the observed difference between
all measurements was significant post hoc Tukey’s test
was performed. Statistical significance was considered
to be achieved for p ≤ 0.05. All the calculations were
performed by means of Statistica v 9.0 computer software.15-18 months post 17 2.86 ± 0.63
MMP-9/TIMP-1 before radioiodine 23 4.16 ± 3.19 0.042
7 days post 21 3.40 ± 2.06
3 months post 23 3.39 ± 1.47
6 - 8 months post 23 3.00 ± 1.95
15-18 months post 17 2.92 ± 1.68
Table 2 Descriptive statistics for serum concentrations of
matrix metaloproteinases (MMP-2, MMP-9), tissue
inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2),
adiponectin and thrombospondin-1 (TSP-1) at five (5)
consecutive visits – before and after radioiodine therapy,
presented with probability values (p-values) of
Kruskal-Wallis’ ANOVA for repeated measures design
VISIT: n Mean ± SD p-value
MMP-2 [ng/ml] before radioiodine 23 393 ± 106 0.001
7 days post 23 373 ± 88
3 months post 23 423 ± 115
6 - 8 months post 23 452 ± 124
15-18 months post 17 774 ± 424
MMP-9 [ng/ml] before radioiodine 23 631 ± 327 0.68
7 days post 23 594 ± 353
3 months post 23 704 ± 364
6 - 8 months post 23 714 ± 430
15-18 months post 17 470 ± 106
TIMP-1 [ng/ml] before radioiodine 23 177 ± 76 0.00001
7 days post 23 186 ± 54
3 months post 23 215 ± 86
6 - 8 months post 23 263 ± 128
15-18 months post 17 296 ± 118
TIMP-2 [ng/ml] before radioiodine 23 136 ± 44 0.36
7 days post 23 143 ± 36
3 months post 23 161 ± 39
6 -8 months post 23 153 ± 39
15-18 months post 17 168 ± 41
Adiponectin [ng/ml] before radioiodine 23 16442 ±9490 0.001
7 days post 23 14430 ± 6216
3 months post 23 21300 ± 8908
6 - 8 months post 23 20005 ± 8056
15-18 months post 17 23518 ± 9840
TSP-1 [ng/ml] before radioiodine 23 31246 ± 10680 0.72
7 days post 23 32761 ± 9046
3 months post 23 32507 ± 10892
6 - 8 months post 23 33751 ± 8830
15-18 months post 17 31758 ± 8319The study was approved by the Ethics Committee of
the Medical University of Lodz, Poland.
Results
Results of the study are presented in Tables 1, 2 and 3
and Figures 1, 2, 3 and 4. Following radioiodine treat-
ment there was a fall in free T4 between visit 2 and visit
3 (p < 0.01), however, as patients later developing hypo-
thyroidism were treated with L-thyroxine, then the con-
centrations of free T4 remained stable at subsequent
visits. Changes of TSH, free T4, free T3, glucose and
lipids at the beginning and at the end of the study are
presented in Table 1. Concentrations of other parame-
ters, measured at subsequent visits (1–5) are presented
in Table 2. There were no acute changes in serum con-
centrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adi-
ponectin and TSP-1 (visit 1 vs. visit 2). There was no
significant change in serum concentrations of TSP-1
throughout the study (Table 2, Figure 1). In contrast to
TSP-1, there was, however, an increase in serum adi-
ponectin (already significant at visit 3, p < 0.05), that
remained significant for further duration of the study
and (16442±9490 ng/ml at visit 1 (before radioiodine ad-
ministration) vs. to 23518±9840 ng/ml, at visit 5 (15–18
months after radioiodine administration), p < 0.01, Table 2,
Figure 2.
Analysis of concentrations of MMPs and their inhi-
bitors revealed no significant change in serum MMP-9
throughout the study, but an increase in MMP-2 (from
393±106 ng/ml, to 774±424 ng/ml) and TIMP-1 (from
177±76 ng/ml to 296±118 ng/ml), visit 1 to visit 5 re-
spectively, p < 0.01. Further analysis, presented in Table 3,
Figures 3 and 4, revealed, however, no significant change
in MMP-2/TIMP-2 ratio. In contrast, there was a sig-
nificant decrease in MMP-9/TIMP-1 ratio (p < 0.05),
Figure 1 Concentrations of thrombospondin-1 (TSP-1) before and after radioiodine administration at consecutive time-points
(visits 1–5), p=0.72 (Kruskal-Wallis’ ANOVA for repeated measures design).
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MMP-9.
Discussion
To the best of our knowledge, this is the first study
where concentrations of TSP-1 were assessed before
and after treatment with radioiodine. Though this is a
negative observation, the lack of any significant change
of serum TSP-1 after treatment with radioiodine is in-
deed highly reassuring. TSP-1 which represents, besidesFigure 2 Concentrations of adiponectin before and after radioiodine
(Kruskal-Wallis’ ANOVA for repeated measures design).thyroglobulin, the main protein secreted by thyroid
cells has been found to play a role in the process of
folliculogenesis [22], and inhibition of apoptosis of thy-
roid cells [23]. Furthermore, it has recently been found
that TSP-1 directly promotes progression of papillary
thyroid carcinoma, and namely BRAF(V600E), i.e. the
most common somatic mutation in papillary thyroid
carcinoma, requires activation of several other genes,
including TSP-1, in order to facilitate tumor invasion
and metastasis [24,25]. Sid et al. [26] also demonstratedadministration at consecutive time-points (visits 1–5), p < 0.01
Figure 3 The ratio of concentrations of matrix metalloproteinases and their respective inhibitors at consecutive time-points (visits
1–5). Matrix metalloproteinase-2 (MMP-2) to tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) ratio, p = 0.34 (Kruskal-Wallis’ ANOVA for
repeated measures design) before radioiodine administration and at all subsequent time-points.
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lignant cells was closely correlated to the amount of
TSP-1. They also demonstrated that exogenously added
TSP-1 stimulated by two-fold the invasiveness of fol-
licular thyroid carcinoma cells, while the use of specific
anti-TSP-1 blocking antibodies led to a drastic inhib-
ition of the basal follicular thyroid carcinoma cell inva-
sion. In such context, the lack of any significant changeFigure 4 The ratio of concentrations of matrix metalloproteinases and
(visits 1–5). Matrix metalloproteinase-9 (MMP-2) to tissue inhibitor of matr
repeated measures design) before radioiodine administration and at all subin serum TSP-1 might signify that radioiodine treat-
ment of thyrotoxicosis is unlikely to influence the de-
velopment of subsequent thyroid cancer. It should be,
however, strongly emphasized that that the observed
lack of any significant changes in serum concentrations
of TSP-1, must be also confirmed on a tissue levels, i.e.
by studies of expression of TSP-1 following radioiodine
treatment in thyroid cells.their respective inhibitors at consecutive time-points
ix metalloproteinase-1 (TIMP-1) ratio, p < 0.05 (Kruskal-Wallis’ ANOVA for
sequent time-points.
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[27], where we demonstrated an unequivocal rise in
serum adiponectin at three months after radioiodine
administration. In this paper we have prospectively car-
ried out our observations up to 15–18 months after
radioiodine treatment, and so we have demonstrated
that raised adiponectin concentrations persisted at all
subsequent time-points. In our opinion, this implies
that an increase in serum adiponectin is a sustained
phenomenon, while longitudinal and prospective nature
of our study diminishes the chance of possible type I (i.e.,
false positive) statistical error. The observed sustained
increase in vasoprotective adiponectin is reassuring,
given some recent controversies regarding cardiovascular
safety of treatment with radioactive iodine. As mentioned
above [6,7], adiponectin improves insulin sensitivity and
exerts anti-atherosclerotic effects in blood vessels. In-
deed there are some studies [28] suggestive that the
plasma leptin/adiponectin ratio predicts first cardiovas-
cular event at least in men. Furthermore many cancer
cell lines express adiponectin receptors, and adipo-
nectin in vitro limits cell proliferation and induces
apoptosis. Recent in vitro studies demonstrate the an-
tiangiogenic and tumor growth-limiting properties of
adiponectin [29]. It is to be recalled, however, that the
significance of total adiponectin concentrations as a
marker of a risk of cardiovascular disease has been re-
cently questioned [30,31].
Current study has also helped to clarify issues associ-
ated with changes of concentrations of MMPs and their
inhibitors following radioiodine administration. In par-
ticular, we have demonstrated that though there was a
significant increase in concentrations of MMP-2, that
was no significant change in MMP-2/TIMP-2 ratio; the
latter possibly being a result of a concomitant (though
not significant) increase in TIMP-2 concentrations (from
136±44 ng/ml to 168±41 ng/ml). In contrast, there was
no change in serum MMP-9 concentrations but there
was a significant increase in TIMP-1 concentrations,
with subsequent fall in MMP-9/TIMP-1 ratio. It should
be mentioned that TIMP-2 is the principal inhibitor of
MMP-2, while TIMP-1 is the principal inhibitor of MMP-
9 [32], hence these results are suggestive of possible
fall in free (i.e., biologically active) MMP-9 concentra-
tions following radioiodine treatment. Interestingly, the
observed increase of serum TIMP-1 concentrations seems
to be independent of TSP-1, even though there is some
evidence that TSP-1 induced expression of TIMP-1 in
follicular thyroid carcinoma cells [33]. Therefore, our data
support a notion - expressed previously - that treatment
with radioactive iodine appears safe [34], as evidenced in
children treated with radioactive iodine for Graves’ disease
[35]. We have, already mentioned in our previous paper
[27] that cardiovascular safety of radioactive iodine wouldalso depend on meticulous follow-up of patients who
undergo this treatment, as efforts must be made to detect
and to treat radioiodine-induced hypothyroidism. If this
is not done properly, then hypothyroidism per se might
increase a risk of subsequent cardiovascular disease
[36-38]. It should also be mentioned that stable con-
centrations of MMPs, with possible fall of free MMP-9,
do not support a notions of significant involvement of
MMPs in the development of neoplasms following treat-
ment with radioactive iodine. In this context, we note
that large study of Ron et al. [39], based on a data from
35 593 subjects, failed to reveal an increase in cancer
mortality in subjects treated with radioiodine.Conclusions
In summary, results of our study are reassuring in terms
cardiovascular and neoplastic safety of radioiodine treat-
ment of thyrotoxicosis. In particular, administration of
radioiodine does not alter serum concentrations of pro-
inflammatory and procancerogenic TSP-1, and is asso-
ciated with a sustained increase in serum adiponectin.
Furthermore, there is no change in MMP-2/TIMP-2 ra-
tio, with an increase in TIMP-1, and a fall of MMP-9
/TIMP-1 ratio is recorded, the latter possibly indicative
of a fall in free MMP-9 concentrations. However, it must
be stressed that in our study we assessed concentrations
of indirect markers associated with the risk of cardiovas-
cular and neoplastic diseases, which cannot be regarded
as surrogates of hard clinical end-points, such as mor-
bidity and mortality.Competing interests
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